Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: enclosed (41), roofed (14), sheltered (10)

UHS self-certification NHS provider licence conditions G6 and CoS7

Description: Worksheet "G6 & CoS7" Financial Year to which self-certification relates 2021/22 Please complete the explanatory information in cell Declarations required
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/NHS-Improvement-declaration-conditions-G6-and-CoS7.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

Tilt table test for children - patient information

Description: This factsheet provides information about your child having a tilt table test.
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Tilt-table-test-for-children-644-PIL.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

Daratumumab SC Ver1

Description: Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

SOP validation dose banding Aria ver1

Description: Central South Coast Cancer Network Standard Operating Procedure Validation of CSCCN Dose Banding in Aria (SOP:CH004) 1. Objective 1.1
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Validation/SOPvalidationdosebandingAriaver1.pdf

UHS Clinical Research Engagement Internship 2022 - Advert

Description: UHS Clinical Research Engagement Internship 2022 The UHS strategic vision (UHS, 2021) outlines clearly the need to continue to embed clinical
Url: /Media/Southampton-Clinical-Research/Downloads/UHS-Clinical-Research-Engagement-Internship-2022-Advert.pdf

Stress-dose steroid treatment following zoledronic acid infusion - patient information

Description: This factsheet has been written to provide you with important information following your child's treatment with zoledronic acid.
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Stress-dose-steroid-treatment-following-zoledronic-acid-infusion-3003-PIL.pdf

Institutional information_2021_final

Description: Institutional information – key facts for inclusion as appropriate Support statements must be personal to your application to avoid the same document
Url: /Media/Southampton-Clinical-Research/Grants/Download/Institutional-information-2021-final.pdf

BRC Global-NAMRIP Application form Oct 20

Description: Global-NAMRIP NIHR Southampton Biomedical Research Centre (BRC) and Global Network for Anti-Microbial Resistance and Infection Prevention (Global-NAMRIP) Pr
Url: /Media/Southampton-Clinical-Research/Grants/BRC-Global-NAMRIP-Application-form-Oct-20.docx

211 to 220 of 408

Previous … 20 21 22 23 24 … Next